World Solve

Counterfeit medications sold through unauthorized online channels can be difficult to distinguish from legitimate products without lab testing, putting patients at serious risk. Scalable, affordable detection at the point of purchase remains an unresolved challenge.

Dependency on imported medicines increases vulnerability to global supply shocks and raises prices. Regional pharma manufacturing hubs and harmonized regulatory standards could improve medicine security.

Medicines used on Earth lose potency rapidly on orbit, endangering astronauts on long multi-year Mars missions. Developing radiation-shielded drug formulations and long-shelf-life stabilizing active compounds is required.

In major agricultural and industrial manufacturing regions across East and South Asia, overuse of antibiotics in livestock and unmonitored factory discharge have accelerated the proliferation of drug-resistant pathogens, threatening global healthcare systems.

Poor supply chain oversight allows fake antibiotics, malaria medications, and life-saving drugs to enter rural retail markets, leading to treatment failures and drug resistance.

Foreign pharmaceutical companies patent compounds derived from traditional Asian herbal knowledge without benefit-sharing agreements with native communities.

Sophisticated fake prescriptions generated with AI assistance can be difficult for pharmacies to distinguish from legitimate ones without additional verification steps. Closing this gap remains an urgent unresolved challenge for pharmaceutical safety.

Bacteria are evolving resistance faster than pharmaceutical companies are creating new antibiotics to fight them. Left unresolved, common infections could become deadly again within a few decades.

Build transparent testing, traceability, and regulatory methods for identifying heavy metals, steroids, pharmaceuticals, and contaminants in traditional medicine supply chains.

Despite recognition of its importance, reliable methods for biotechnologies enabling the production of pharmaceuticals and fine chemicals from renewable feedstocks are still lacking. Progress is hindered by incomplete mechanistic knowledge, high capital and operational barriers, and the absence of deployment models suited to the contexts of greatest need.